Cargando…

Effects of exendin-4, a glucagon like peptide-1 receptor agonist, on neutrophil count and inflammatory cytokines in a rat model of endotoxemia

BACKGROUND: Sepsis remains a major cause of morbidity and mortality. A variety of strategies targeting modulation of the pro-inflammatory response associated with early sepsis have been reported without clinical success. GLP-1 enhances glucose-stimulated insulin secretion. In addition, it was shown...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yanay, Ofer, Bailey, Adam L, Kernan, Kelly, Zimmerman, Jerry J, Osborne, William R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521677/ https://www.ncbi.nlm.nih.gov/pubmed/26244029 http://dx.doi.org/10.2147/JIR.S84993

Ejemplares similares

Signalling, trafficking and glucoregulatory properties of glucagon‐like peptide‐1 receptor agonists exendin‐4 and lixisenatide
por: Pickford, Philip, et al.
Publicado: (2020)

Indirect Effects of Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 on the Peripheral Circadian Clocks in Mice
por: Ando, Hitoshi, et al.
Publicado: (2013)

Glucagon-Like Peptide-1 Agonist Exendin-4 Facilitates the Extinction of Cocaine-Induced Condition Place Preference
por: Zhu, Changliang, et al.
Publicado: (2021)

Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia
por: Teramoto, Shinichiro, et al.
Publicado: (2011)

Differential hypoglycaemic, anorectic, autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret
por: Lu, Zengbing, et al.
Publicado: (2014)

The glucagon-like peptide-1 receptor agonist exendin-4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia
por: Chen, Fangzhe, et al.
Publicado: (2016)

Effects of Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 on the Reinstatement of Cocaine-Mediated Conditioned Place Preference in Mice
por: Zhu, Changliang, et al.
Publicado: (2022)

Differences in the Central Anorectic Effects of Glucagon-Like Peptide-1 and Exendin-4 in Rats
por: Barrera, Jason G., et al.
Publicado: (2009)

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
por: Arakawa, Masayuki, et al.
Publicado: (2010)

Systematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist
por: Sai, Wenbo, et al.
Publicado: (2017)

Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking
por: Lucey, Maria, et al.
Publicado: (2021)

The Glucagon-Like Peptide 1 Analogue, Exendin-4, Attenuates the Rewarding Properties of Psychostimulant Drugs in Mice
por: Egecioglu, Emil, et al.
Publicado: (2013)

Therapeutic Effect of Exendin-4, a Long-Acting Analogue of Glucagon-Like Peptide-1 Receptor Agonist, on Nerve Regeneration after the Crush Nerve Injury
por: Yamamoto, Koji, et al.
Publicado: (2013)

Glucagon-like peptide-1 analogue exendin-4 modulates serotonin transporter expression in intestinal epithelial cells
por: Cui, Xiufang, et al.
Publicado: (2020)

Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits hyperglycemia-induced apoptosis in myocytes by suppressing receptor for advanced glycation end products expression
por: YI, BO, et al.
Publicado: (2014)

The Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 Inhibits Lipopolysaccharide-Induced Osteoclast Formation and Bone Resorption via Inhibition of TNF-α Expression in Macrophages
por: Shen, Wei-Ren, et al.
Publicado: (2018)

Anti-inflammatory Effect of Glucagon Like Peptide-1 Receptor Agonist, Exendin-4, through Modulation of IB1/JIP1 Expression and JNK Signaling in Stroke
por: Kim, Soojin, et al.
Publicado: (2017)

Role of Renal Sympathetic Nerves in GLP‐1 (Glucagon‐Like Peptide‐1) Receptor Agonist Exendin‐4‐Mediated Diuresis and Natriuresis in Diet‐Induced Obese Rats
por: Liu, Xuefei, et al.
Publicado: (2021)

Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes
por: Raven, Lisa M, et al.
Publicado: (2022)

(64)Cu Labeled Sarcophagine Exendin-4 for MicroPET Imaging of Glucagon like Peptide-1 Receptor Expression
por: Wu, Zhanhong, et al.
Publicado: (2014)

Exendin-4, a glucagon-like peptide-1 analogue accelerates healing of chronic gastric ulcer in diabetic rats
por: Chen, Yen-Cheng, et al.
Publicado: (2017)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Radioiodinated Exendin-4 Is Superior to the Radiometal-Labelled Glucagon-Like Peptide-1 Receptor Probes Overcoming Their High Kidney Uptake
por: Läppchen, Tilman, et al.
Publicado: (2017)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

The Role of Glucagon-Like Peptide 1 Receptor PET/CT With Ga-68-NODAGA-exendin in Localising an Insulinoma: Lessons From a Clinical Case
por: Grigoriadou, Viktoria Chatzimavridou, et al.
Publicado: (2021)

Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model
por: Zhang, Ling-Yu, et al.
Publicado: (2021)

Glucagon-Like Peptide-1 Analog Exendin-4 Ameliorates Cocaine-Mediated Behavior by Inhibiting Toll-Like Receptor 4 Signaling in Mice
por: Zhu, Changliang, et al.
Publicado: (2021)

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists
por: Zhang, Yu-Juan, et al.
Publicado: (2013)

Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012)

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017)

The potential of glucagon-like peptide-1 receptor agonists in heart failure
por: Kreiner, Frederik Flindt, et al.
Publicado: (2022)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
por: Delgado, A., et al.
Publicado: (2021)

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
por: Wojtara, Magda, et al.
Publicado: (2023)

Anti‐inflammatory effects of exendin‐4, a glucagon‐like peptide‐1 analog, on human peripheral lymphocytes in patients with type 2 diabetes
por: He, Lan, et al.
Publicado: (2013)

Glucagon‐like peptide‐1 receptor agonist prescribing patterns in adolescents with type 2 diabetes
por: Bensignor, Megan O., et al.
Publicado: (2022)

It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
por: Oberle, Megan M., et al.
Publicado: (2019)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
por: Gurung, Tara, et al.
Publicado: (2015)

Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
por: Lorenz, Martin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_93dsrhhaj1ssqemltgo9c9gdjq